MedTrace Logo

The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome

NCT00664742 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 614

Last updated 2011-05-17

Study results available
· View outcomes & findings →

Summary

This study evaluated safety, tolerability and efficacy of Fluvastatin XL® -extended release (80 mg once daily) in patients with metabolic syndrome

Conditions

  • Metabolic Syndrome

Interventions

DRUG

Fluvastatin XL®

Fluvastatin extended release 80 mg

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2007-10-31
Completion
2007-10-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00664742 on ClinicalTrials.gov